The PathPlex™ IHC multiplex antibody panels from Bethyl allow for the visualisation of multiple targets within a single tissue section. Unlike traditional IHC methods, which cannot differentiate between multiple cells types or targets without serial sections, these panels quickly detect multiple antigens in a single section to gain a clear understanding of the tumour microenvironment whilst preserving tissue architecture.
Benefits of using IHC PathPlex panels
• Quickly detect multiple antigens in a single tissue section
• Tissue architecture is preserved
• Ideal for IHC in limited samples
• Obtain co-expression & spatial data from within the tumour microenvironment
• Low-level binding sites detected
• Intensity for each target measured – signals can be overlaid & seen as single or multi- channel
• Compatible with any mouse & rabbit primary antibody combination
Detection of human CD3 (yellow), CD8 (red), and CD20 (green) using PathPlex Lymphocyte panel in FFPE tonsil by IHC-IF. Rabbit anti-CD3e recombinant monoclonal [BL-298-5D12] (A700-016), rabbit anti-CD8a recombinant monoclonal [BLR044F] (A700-044), mouse anti-CD20 monoclonal [L26] (A500-017A). Secondary: HRP-conjugated goat anti-rabbit IgG (A120-501P) and HRP-conjugated goat anti-mouse IgG (A90-116P). Substrate: Opal™ 520, 620, and 690. Counterstain: DAPI (blue)
Detection of human CD3 (green), CD20 (magenta), CD68 (yellow) using PathPlex T, B & M Panel, and Cytokeratin (red) in FFPE tonsil by IHC-IF. Antibodies: CD3 (A700-016), CD20 (A500-017A), CD68 (A500-018A), Cytokeratin (A500-019A). Substrate: Opal™ reagent. Counterstain: DAPI (blue).
|T-cell immuno-oncology panel||CD3E, CD8 alpha, PD-L1||Base panel for checkpoint inhibition and T-cell activation. This panel measures number of total T-cells (CD3) and activated T-cells (CD8) in context of one of the major checkpoint inhibitors, PD-L1. Can be combined with other markers such as cytokeratin to also label tumour cells or CD68 to measure macrophages.|
|Lymphocyte panel||CD3E, CD8 alpha, CD20||Base panel for lymphocyte infiltration. This panel measures number of total T-cells (CD3), activated T-cells (CD8), total B-cells (CD20). Can be combined with other markers such as cytokeratin to also label tumour cells.|
|T, B & M panel||CD3E, CD68, CD20||Base panel for measuring lymphocyte and macrophage cells. This panel detects T-cells (CD3), B-cells (CD20) and macrophages (CD68). Can be combined with other markers such as cytokeratin to also label tumour cells.|
• Immunohistochemistry Immunofluorescence (IHC-IF)
• Multiplex Immunofluorescence (mIF)
Material available for download
PathPlex IHC Multiplex Antibody Panels brochure
Note: product availability depends on country - see product detail page.
|Details||Cat number & supplier||Size||Price|
|PathPlex® Panel 1 (CD3E, CD8 alpha, PD-L1) A810-001 · Bethyl Laboratories, Inc.||
A810-001Bethyl Laboratories, Inc.
|PathPlex® Panel 2 (CD3E, CD8 alpha, CD20) A810-002 · Bethyl Laboratories, Inc.||
A810-002Bethyl Laboratories, Inc.
|PathPlex® Panel 3 (CD3E, CD68, CD20) A810-003 · Bethyl Laboratories, Inc.||
A810-003Bethyl Laboratories, Inc.